Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actinogen Medical ( (AU:ACW) ) has shared an announcement.
Actinogen Medical announced that its CEO, Dr. Steven Gourlay, presented at the Canaccord Drug & Device Conference, highlighting the company’s progress with Xanamem, an oral therapy targeting brain cortisol to treat Alzheimer’s and depression. The presentation emphasized the drug’s promising clinical development, upcoming milestones, and its potential to meet the high demand for effective Alzheimer’s treatments. Actinogen’s ongoing clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, demonstrate significant benefits in managing symptoms, reinforcing Xanamem’s potential impact on the market.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential applications in other conditions like Fragile X Syndrome. The company aims to address the substantial unmet medical need for new treatments in these areas.
YTD Price Performance: 20.0%
Average Trading Volume: 2,595,143
Technical Sentiment Signal: Hold
Current Market Cap: A$95.26M
Learn more about ACW stock on TipRanks’ Stock Analysis page.